All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Gastroenterology Drugs in Phase II/III Clinical Development in IRELAND

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Allergan plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

AstraZeneca Regains Global Rights to Brazikumab From Allergan

Contact the Supplier

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 11, 2020

Details:

AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.

Allergan plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Contact the Supplier

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.